Medtronic’s Q3 Profit In Line With Expectation Despite COVID-19 Impact On Procedure Volume
Medtronic Plc's (NYSE: MDT) Q3 FY22 sales of $7.76
Medtronic Q3 Adj. EPS $1.37, Inline, Sales $7.80B Miss $7.90B Estimate
Medtronic (NYSE:MDT) reported quarterly earnings of $1.37 per share which met the analyst consensus estimate. This is a 6.2 percent increase over earnings of $1.29 per share from the same period last year. The company
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell
• Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Medtronic Receives FDA Expanded Approval For Cardiac Cryoablation Catheters For Pediatric Treatment Of A Common Heart Rhythm Condition
studies, also observed high efficacy rates and low adverse events.2-17
The Freezor cardiac cryoablation catheter was first commercially available in the U.S. for adult use of AVNRT in 2003, followed by the
Raymond James Maintains Outperform on Medtronic, Lowers Price Target to $116
Raymond James analyst Jayson Bedford maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $127 to $116.
Expert Ratings For Medtronic
Within the last quarter, Medtronic (NYSE:MDT) has observed the following analyst ratings:
Piper Sandler Maintains Neutral on Medtronic, Lowers Price Target to $105
Piper Sandler analyst Matt O'Brien maintains Medtronic (NYSE:MDT) with a Neutral and lowers the price target from $110 to $105.